Tranexamic acid for the treatment of postpartum haemorrhage: An international, randomised, double blind, placebo controlled trial

ondon School of Hygiene and Tropical Medicine0 个研究点目标入组 0 人开始时间: 2010年2月9日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Immediately after delivery, all usual care should be given for the prevention of PPH. If bleeding continues and a clinician diagnosis of PPH is made, all usual treatments should be given and at the same time assessment for inclusion in the WOMAN Trial should be done. As most women die within 2 - 4 hours of delivery, it is important to consider inclusion as early as possible. Clinician diagnosis of PPH may be based on any of the following:
•1. Blood loss after vaginal delivery greater than 500 ml, or
•2. Greater than 1000 ml after caesarian section, or
•3. Blood loss enough to compromise the haemodynamic status of the woman
•Other inclusion criteria:
•4. All women who are clinician-diagnosed with postpartum haemorrhage following vaginal delivery or caesarean section
•5. Consent has been obtained in line with local procedures

•1. Women for whom the responsible clinician considers there is a clear indication for TXA should not be randomised.
•2. Women for whom the responsible clinician considers there is a clear contraindication for TXA should not be randomised.
•There are no other pre-specified exclusion criteria. Where the responsible clinician is substantially uncertain as to whether or not to use an antifibrinolytic agent in a particular woman with postpartum haemorrhage, the woman should be randomised.

发起方

ondon School of Hygiene and Tropical Medicine